(Q35166521)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

Jean-Michel Pawlotsky

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

Jean Michel Pawlotsky

series ordinal

1

1 reference

6 August 2017

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Prevention and treatment of hepatitis C in injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Effect of alpha interferon on the hepatitis C virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Viruses and interferon: a fight for supremacy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

The immunopathogenesis of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Hepatitis C virus genetic variability: pathogenic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Structural biology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Actions of cytokines on the immune response and viral interactions: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Viral heterogeneity of the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Hepatitis C in the HIV-Infected Person

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Influence of three successive antiviral treatments on viral heterogeneity in nonresponder chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900088-3

7 January 2021

10.1016/S0166-3542(03)00088-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834855%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference